Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SMAD4
REST API REST API
Homo sapiens
SMAD4 is differentially expressed in 316 experiments: 145 organism parts: lung, bone marrow, ... (143 more);, 200 disease states: normal, control, ... (198 more);, 97 cell types 426 cell lines 45 compound treatments and 87 other conditions.
Synonyms MADH4, DPC4
Orthologs B0JYL0_BOVIN (Bos taurus)   SMAD4_RAT (Rattus norvegicus)   Smad4 (Mus musculus)   SMAD4 (1 of 2) (Danio rerio)   ENSCING00000015941 (Ciona intestinalis)   SMAD4 (2 of 2) (Danio rerio)   Q4H2T4_CIOIN (Ciona intestinalis)   Med (Drosophila melanogaster)   smad4 (Xenopus laevis)   Q6JDJ5_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, negative regulation of cell growth, DNA binding, negative regulation of transcription, DNA-dependent, protein binding, regulation of transcription, DNA-dependent, cytoplasm, cell proliferation, regulation of cell proliferation, intracellular, negative regulation of cell proliferation, protein complex, transcription, DNA-dependent, developmental growth, BMP signaling pathway, transforming growth factor beta receptor signaling pathway, response to hypoxia, positive regulation of transforming growth factor beta receptor signaling pathway, regulation of transforming growth factor beta receptor signaling pathway, sequence-specific DNA binding, identical protein binding, endoderm development, positive regulation of transcription from RNA polymerase II promoter, centrosome, nucleus, mesoderm development, transcription factor complex, chromatin binding, protein homodimerization activity, SMAD binding, nucleoplasm, gastrulation, regulation of transcription from RNA polymerase II promoter, positive regulation of transcription, DNA-dependent, positive regulation of epithelial to mesenchymal transition, regulation of binding, sebaceous gland development, in utero embryonic development, kidney development, branching involved in ureteric bud morphogenesis, somite rostral/caudal axis specification, response to transforming growth factor beta stimulus, gastrulation with mouth forming second, tissue morphogenesis, activin responsive factor complex, SMAD protein complex assembly, transforming growth factor beta receptor, common-partner cytoplasmic mediator activity, neural crest cell differentiation, negative regulation of cell death, collagen binding, neuron fate commitment, palate development, nephrogenic mesenchyme morphogenesis, formation of anatomical boundary, R-SMAD binding, SMAD protein signal transduction, negative regulation of protein catabolic process, positive regulation of pathway-restricted SMAD protein phosphorylation, I-SMAD binding, metanephric mesenchyme morphogenesis, sequence-specific DNA binding transcription factor activity, core promoter proximal region sequence-specific DNA binding, positive regulation of SMAD protein import into nucleus, protein binding transcription factor activity, transcription regulatory region DNA binding, SMAD protein complex, anterior/posterior pattern specification, regulation of hair follicle development, regulation of transforming growth factor beta2 production
InterPro Term MAD_homology1_Dwarfin-type, SMAD_dom_Dwarfin-type, MAD_homology_MH1
Gene-Disease Assocation JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME;, PANCREATIC CANCER, COLORECTAL CANCER; CRC, JUVENILE POLYPOSIS SYNDROME; JPS
UniProt Accession Q13485, Q9BYG6, E7EUB6
Search EB-eye ENSG00000141646
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (39 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639, E-GEOD-3529
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
SW480
3
E-MTAB-37, E-GEOD-18005, E-MEXP-1014
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
HCC1937
2
E-MTAB-37, E-MTAB-62
MDA468
2
E-MEXP-440, E-MTAB-62
420 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, E-GEOD-3998, ... (50 experiments)

Factor Value U/D Experiments
centroblast
2
E-TABM-702, E-GEOD-15271
fibroblast
2
E-GEOD-3920, E-GEOD-3204
human embryonic stem cell
2
E-GEOD-20033, E-GEOD-18265
iPS cells from episomal vectors (Defined Factor)
1
E-GEOD-20033
cardiac myocyte
1
E-AFMX-5
native skin
1
E-GEOD-3204
91 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-TABM-15, E-GEOD-16363, ... (69 experiments)

Factor Value U/D Experiments
sarcoma
2
E-GEOD-2719, E-MTAB-62
lung adenocarcinoma
2
E-MEXP-231, E-GEOD-2514
benign prostatic hyperplasia
2
E-MEXP-2034, E-MEXP-1243
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-1729
acute quadriplegic myopathy
2
E-GEOD-3307, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
194 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-5824, E-MEXP-1958, E-MEXP-941, ... (25 experiments)

Factor Value U/D Experiments
none
2
8
E-GEOD-5824, E-MEXP-1958, E-GEOD-412, E-GEOD-2803, E-GEOD-7307, ... (10 experiments)
ethanol
2
E-MEXP-2241, E-GEOD-3113
baseline propofol
1
E-GEOD-4386
glutamine
1
E-MEXP-941
granulocyte-colony stimulating factor
1
E-GEOD-7400
4,5-dianilinophthalimide
1
1
E-GEOD-5258
39 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-GEOD-17476, E-GEOD-22593, E-TABM-321, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-10315, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-TABM-15, ... (36 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22152, E-GEOD-1493, E-GEOD-22309, E-GEOD-1657, E-GEOD-17636, ... (6 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-12293, E-GEOD-22541, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Processing time: 0.254 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM